<?xml version='1.0' encoding='utf-8'?>
<document id="24091110"><sentence text="Optimizing DAA management in daily practice." /><sentence text="Despite the incontestable benefits of telaprevir and boceprevir-based triple therapy in patients infected with genotype 1, the practitioner faces a number of new challenges"><entity charOffset="38-48" id="DDI-PubMed.24091110.s2.e0" text="telaprevir" /><entity charOffset="53-63" id="DDI-PubMed.24091110.s2.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.24091110.s2.e0" e2="DDI-PubMed.24091110.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24091110.s2.e0" e2="DDI-PubMed.24091110.s2.e1" /></sentence><sentence text=" In daily clinical practice, a checklist approach may facilitate the management of triple therapy" /><sentence text=" Before initiation, several specific issues should be reviewed with the patient in order to optimize adherence and treatment outcome: potential drug to drug interaction, treatment duration and stopping rules, possible treatment outcomes, side effects, dose and administration with food advice, management of side effects" /><sentence text=" Because treatment failure is associated with the emergence of resistance-associated variants with reduced sensitivity to protease inhibitors, adherence is of major importance" /><sentence text=" In this setting, the role of educational nurse should be emphasized for the management of triple therapy in daily clinical practice" /><sentence text=" " /></document>